Immune-Onc Therapeutics Inc.

Coya Therapeutics, Inc. launched the final biopharmaceutical initial public offering in the US in 2022 on 29 December, raising $15.25m from the sale of 3.05 million shares at $5 each, which brought t

To hear OncoResponse Inc . CEO Clifford Stocks tell it, his company is “approaching that interesting time point where pharma likes to partner” as it readies lead candidate OR2805 for efficacy studies

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held

AbCellera Secures $10m Series A Investment AbCellera Biologics Inc. raised $10m in its Series A financing round led by DCVC Bio, which adds 2 board seats. (Sep.) Founded in 2012 based on microfluidi